The neonatal transport team was called to transport a 3-day-old male infant who had stopped nursing and became jittery and hypothermic. He was born at 37 weeks' gestation to a 34-year-old gravida 3, para 2 mother; his birth weight was 2694 g. Mother's prenatal laboratory studies were blood type B + , VDRL-negative, Hepatitis B surface antigen-negative, rubella-immune and HIVnegative. Her pregnancy was uncomplicated. The presentation was vertex and the route of delivery was by Cesarean section with labor. APGAR scores were 9 at 1 minute and 9 at 5 minutes; he did not require cardiopulmonary resuscitation.
The patient did well until early on day of life 3 when he stopped nursing. He was supposed to be discharged to home later that day, but his father noted noisy breathing and grunting. Neonatology was consulted at this point in time. His physical examination was remarkable for hypertonia and jitteriness involving all four extremities. These movements could be stopped but would restart again. His rectal temperature was 36.5 8C. He had also lost 270 g since birth. His oxygen saturation was 96% while breathing room air. An arterial blood was obtained: pH 7.41, p a CO 2 26 mm Hg, p a O 2 95 mm Hg and a base excess of À6 (in room air). The blood pressure was noted to be elevated. Additional laboratory studies included: total bilirubin of 9 mg%, electrolytes including Na + of 149 mEq/l, K + of 6.9 mEq/l, Cl of 111 mEq/l, total Ca of 8.6 mg% and a glucose screen of >80 mg%. White blood cell count was 16,800, and hematocrit and platelet counts were 48% and 484,000, respectively. SGPT was 34 and a blood culture was drawn. A peripheral venous line was placed and the infant was started on 10% dextrose with electrolyte solution and, because of a low urine output, he was also given a bolus of 10 ml/kg 5% albumin. Ampicillin and gentamicin were started as well. By the time the neonatal transport team arrived, he required supplemental oxygen of 35% to 40%. His heart rate was 170 to 180 beats/min and his lungs sounded ''wet'' at that time. A chest radiograph showed borderline normal-sized heart and bilateral fluffy infiltrates in the lungs. He was also noted to have significant abdominal distention. An orogastric tube was placed and 5 ml of fresh blood was suctioned from the stomach. The baby was transported without difficulty. Upon arrival to the Neonatal Intensive Care Unit, an arterial blood gas was obtained and results included: pH 7.17, p a CO 2 55 mm Hg, p a O 2 of 147 mm Hg and a base deficit of À10. He was then intubated and was placed on a ventilator. It became evident that he had suffered a severe pulmonary hemorrhage. A plasma ammonia level of >2000 M/l directed the diagnosis.
DENOUEMENT AND DISCUSSION
Hyperammonemia is often the sign of an underlying metabolic disturbance. Normally, excess dietary and waste nitrogen, which remain after protein synthesis, are converted to urea through the urea cycle. Urea is produced in the liver where the urea cycle converts 80% of excreted nitrogen. The five enzymes that make up the urea cycle ( Figure 1 ) are regulated long term by the quantity of protein in the diet. 1 Disorders of any of the urea cycle enzymes lead to accumulation of ammonia and its precursors. This can lead to encephalopathy and death or devastating neurologic sequelae if not treated promptly. 1 
CLINICAL MANIFESTATIONS
Most infants with severe deficiency of urea cycle enzymes present similarly to our patient: a full-term infant who was normal at birth but then developed progressive signs and symptoms of encephalopathy. 1 -3 Elevated plasma ammonia levels that exceed three times the normal (normal levels are <50 M/l) are considered toxic. The clinical manifestations are poor feeding, anorexia, behavioral changes, irritability, vomiting, lethargy, ataxia and seizures. The earliest symptoms are poor feeding and lethargy. Other important early warning signs may also include tachypnea or respiratory distress.
Hyperammonemia may cause central hyperventilation resulting in a respiratory alkalosis. This can also be an early warning sign of a urea cycle disorder. 1, 4 Hyperammonemia and/or other inborn errors of metabolism should be high in the differential diagnosis (Table 1) , especially when a full-term infant presents in respiratory distress in the first few days of life. Inborn errors of metabolism may mimic sepsis and respiratory disorders that are common.
Perinatal/Neonatal Casebook
Physicians should add a plasma ammonia level to the initial bloodwork, especially when there is no obvious source of infection.
If it progresses, the infant may fall into a coma and require endotracheal intubation and assisted ventilation. Circulatory collapse and cerebral edema may occur.
1
Transient hyperammonemia is seen more commonly in premature infants. Transient hyperammonemia in the newborn may be mild [ammonia (NH 3 )=40-50 M/l] or severe (NH 3 near 4000 M/l). The mild form may last for 6 to 8 weeks without symptoms. These infants do not have any neurologic sequelae. 2 The severe form of transient hyperammonemia in the newborn occurs most commonly in premature infants, often in conjunction with respiratory distress. In reported cases, the plasma ammonia level rose quickly during the first few days of life leading to central nervous system depression and coma. 3 The cause remains unknown; though it is apparently not genetic. Therapy is focused on reducing plasma ammonia levels, and dialysis, preferably hemodialysis, may be necessary. The prognosis for aggressively treated infants appears good and transient hyperammonemia in the newborn does not recur in these infants.
EPIDEMIOLOGY
The overall incidence of the five urea cycle enzyme deficiencies is 1/10,000 live births. 1 All disorders of ammonia metabolism are inherited as autosomal recessive defects except for ornithine transcarbamylase deficiency that has an X-linked inheritance pattern. Ornithine transcarbamylase is the most common defect. Genetic analysis of the present case demonstrated arginosuccinic aciduria (Table 2) .
DIAGNOSTIC TESTS
Once hyperammonemia is established, then further laboratory testing is required to determine the specific diagnosis. Repeat plasma ammonia levels should be obtained frequently during the acute stage. A reminder is that proper processing of the blood is of utmost importance so that levels are truly reflective. The choice of drawing arterial blood is well known; however, venous blood may be sufficient; capillary blood is not suitable. Barsotti discusses the steps in order to get an accurate level; these include the following.
o Ideally, the patient should fast for at least 6 hours before drawing the sample;
o Ammonia-free heparin should be used (heparin is the choice because it has been shown to reduce red blood cell ammonia production; 5 o A chilled heparinized vacuum tube that is immediately placed in ice;
o The plasma should be separated within 15 minutes. If allowed to sit, the blood and plasma ammonia concentration will spontaneously increase secondary to ongoing production of ammonia from the red blood cells and the deamination of amino acids, especially glutamine. 5 Standing at room temperature, red blood cell hemolysis and delay in sample processing are also important to avoid since one or all may factitiously increase the plasma ammonia level. Proper processing is felt to be more important than whether the sample is drawn from an artery or vein according to the Consensus Statement from the Conference for the Management of Patients with Urea Cycle Disorders. 6 Serum electrolytes and arterial blood gases initially will help with immediate management. Liver function tests including partial thrombin time, partial tissue thromboplastin time, transaminases, bilirubin and albumin aid in determining the possibility of liver insufficiency as the cause of hyperammonemia. 4 The specific diagnosis for many of these disorders can be established with quantitative plasma amino acids. Urinary amino acids will rule out disorders such as: hyperornithinemia, hyperammonemia, homocitrullinemia and lysinuric protein intolerance. Other tests may be necessary, such as: skin fibroblasts for citrullinemia and a liver biopsy which may be significant for evidence of portal fibrosis in argininosuccinic aciduria. 1 
TREATMENT DURING INITIAL PRESENTATION
Hyperammonemia is a medical emergency. The longer the patient remains in a coma due to hyperammonemia, the worse the prognosis. 1 Prior to transport to a tertiary care center, endotracheal intubation to support or assist ventilation and prevent hypoxemia may be necessary; the placement of a central line such as an umbilical arterial and/or an umbilical venous catheter may be helpful in management of fluids, acidosis and supporting blood pressure. The next goal is to remove exogenous protein. Hemodialysis is the only means of rapidly removing ammonia from the body. 6, 8 Peritoneal dialysis does not remove ammonia quickly enough to minimize brain injury. 1, 7, 8 While preparing for hemodialysis or extracorporeal membrane oxygenation, ammonia scavenging therapy should be initiated, even prior to the diagnosis of a specific metabolic etiology, if it is felt that alteration of the central nervous system status is secondary to the high ammonia level. Loading doses of L -arginine-HCl (600 mg/kg per dose), sodium benzoate (250 mg/kg per dose) and sodium phenylacetate (250 mg/kg per dose) all in 25 to 35 mg/kg 10% dextrose solution given over 90 minutes have been recommended for emergency treatment of newborn infants with hyperammonemia. 1, 4 Sustained infusion of these three medications is recommended over the next 24 hours ( Table 3 ). The doses depend on enzyme deficiency. The mechanism of action of these medications is as follows: benzoate binds glycine to form hippurate, and phenylacetate combines with glutamine, and are then excreted rapidly by the kidney.
Parenteral nutrition is needed to prevent protein catabolism. Use glucose and intravenous fat emulsion, without protein, to maximize calories. Once the ammonia level is <100 M/l and the patient is stable, oral or nasogastric feeds may be initiated using a proteinfree powder. Essential amino acid supplementation may be needed, along with L -citrulline or L -arginine to ''prime'' the urea cycle. Protein should only be withheld for a short period of time. Without protein, the body goes into negative nitrogen balance, which increases the need for nitrogen excretion and worsens the hyperammonemia.
MAINTENANCE THERAPY
There are three parts to maintenance therapy: protein-restricted diet, supplementation with citrulline or arginine, and medication which provides an alternate pathway for waste nitrogen excretion (sodium phenylbutyrate and/or sodium benzoate). 1 The specifics of treatment depend on which enzyme is deficient. A plasma glutamine level is useful as a marker of effective therapy and should be maintained at levels <1000 M/l. 4 Growth, especially length (or height), and development should be monitored closely. Poor growth is a sign of inadequate dietary protein intake. Other services should also be involved: physical, occupational and speech therapy, psychology and genetic counseling.
Intermittent episodes of hyperammonemia can occur despite maintenance therapy. Potential causes include illness or drugs such as valproic acid, haloperidol and anesthetic agents. These episodes can also end in death or severe neurological sequelae. Once again, aggressive treatment is required.
Whenever a patient with a urea cycle defect has symptoms of emesis, lethargy, agitation, disorientation or emotional lability, a plasma ammonia level should be checked. If the ammonia is three times the normal, the child should be hospitalized and treated. Currently, the only way to correct the enzyme deficiency permanently is liver transplant. Gene therapy is the hope of the future. Specifically, the genes for argininosuccinic synthetase and argininosuccinate lyase have been mapped to chromosomes 9 and 7, respectively. 1 
SURVIVAL
Neurologic sequelae and survival depend on the length of the hyperammonemic coma. If the coma is less than 2 days, there is a chance for minimal sequelae, but neurologic deficits usually occur when the coma is longer than 2 days. Since the onset of ''rational treatment,'' the 1-year survival rate for infants ahs been 92%. 1, 7 Many who survive may have neurologic sequelae: mental retardation, seizures, cortical atrophy and spastic quadriparesis. Later acute episodes from protein intake or infection can result in further morbidity and death. Few patients with urea cycle defects live into adulthood. 1 
CONCLUSION
Early diagnosis and management are the key to minimizing neurologic sequelae in infants presenting with hyperammonemia in general and more specifically in infants with urea cycle defects such as the patient presented in this transport casebook who proved to have argininosuccinic aciduria.
Finally, when a term newborn infant presents with signs of mental status changes, emesis, seizures and/or poor feeding, seriously consider adding a plasma ammonia level to the diagnostic work-up.
